NSPXinactive

REBUS HOLDINGS, INC.

Healthcare·Oncology·Pre-clinical
OncologyImmunology

REBUS HOLDINGS, INC. (NSPX): 8 pipeline candidates. Updated within the last hour.

5.7/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health5.0

D/E -1.00 · 400% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth10.0

8 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for REBUS HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

$109K

Runway

—

Revenue

—

Pipeline (8 candidates)

DrugPhase
a2a agonistsPreclinical
a2b antagonistsPreclinical
dual a2a/a2b antagonistsPreclinical
lnc-001Preclinical
lnc-002Preclinical
lnc-003Preclinical
mipsagarginPreclinical
rt-ar001Preclinical

Frequently asked questions

How many drug candidates are in REBUS HOLDINGS, INC.'s pipeline?

REBUS HOLDINGS, INC. (NSPX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is REBUS HOLDINGS, INC.'s lead drug candidate?

REBUS HOLDINGS, INC.'s most advanced tracked candidate is a2a agonists (Preclinical) for inflammatory and autoimmune based diseases.

Get the full picture on REBUS HOLDINGS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar